JO3229B1 - العمل على استقرار الهرمون المنبه للجريب - Google Patents
العمل على استقرار الهرمون المنبه للجريبInfo
- Publication number
- JO3229B1 JO3229B1 JOP/2011/0231A JOP20110231A JO3229B1 JO 3229 B1 JO3229 B1 JO 3229B1 JO P20110231 A JOP20110231 A JO P20110231A JO 3229 B1 JO3229 B1 JO 3229B1
- Authority
- JO
- Jordan
- Prior art keywords
- stabilization
- salts
- fsh
- pharmaceutically acceptable
- addition
- Prior art date
Links
- 230000006641 stabilisation Effects 0.000 title abstract 3
- 238000011105 stabilization Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- -1 alkali metal cations Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 159000000001 potassium salts Chemical class 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Fats And Perfumes (AREA)
Abstract
يتعلق الاختراع الحالي بصفة عامة بمجال تثبيت صيغ الهرمونات المنشطة للحويصلات (FSH)، وبصفة خاصة صيغ FSH السائلة. يتحقق التثبيت بواسطة إضافة أملاح تشتمل على كاتيونات معدنية قلوية مقبولة صيدلانياً، وفي النماذج المفضلة يتحقق التثبيت بإضافة أملاح تشتمل على كاتيونات معدنية قلوية مقبولة صيدلانياً، وفي النماذج المفضلة يتم ذلك من خلال إضافة أملاح مقبولة صيدلانياً، مثل أملاح الصوديوم أو أملاح البوتاسيوم.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171428A EP2417982A1 (en) | 2010-07-30 | 2010-07-30 | Stabilization of gonadotropins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3229B1 true JO3229B1 (ar) | 2018-03-08 |
Family
ID=43216624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2011/0231A JO3229B1 (ar) | 2010-07-30 | 2011-07-21 | العمل على استقرار الهرمون المنبه للجريب |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8993732B2 (ar) |
| EP (3) | EP2417982A1 (ar) |
| JP (3) | JP5860047B2 (ar) |
| KR (2) | KR101991756B1 (ar) |
| CN (2) | CN103052398B (ar) |
| AR (1) | AR082776A1 (ar) |
| AU (1) | AU2011284702C1 (ar) |
| BR (1) | BR112013002312B1 (ar) |
| CA (1) | CA2805864A1 (ar) |
| DK (1) | DK2598160T3 (ar) |
| ES (1) | ES2623634T3 (ar) |
| HR (1) | HRP20170386T1 (ar) |
| HU (1) | HUE033592T2 (ar) |
| IL (2) | IL223821A (ar) |
| JO (1) | JO3229B1 (ar) |
| LT (1) | LT2598160T (ar) |
| MX (2) | MX356951B (ar) |
| NZ (2) | NZ606366A (ar) |
| PL (1) | PL2598160T3 (ar) |
| PT (1) | PT2598160T (ar) |
| RS (1) | RS55772B1 (ar) |
| RU (1) | RU2574012C2 (ar) |
| SA (1) | SA114350786B1 (ar) |
| SI (1) | SI2598160T1 (ar) |
| TW (1) | TWI439283B (ar) |
| WO (1) | WO2012013742A2 (ar) |
| ZA (1) | ZA201209497B (ar) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| HK1223559A1 (zh) * | 2013-11-12 | 2017-08-04 | Cadila Healthcare Limited | 用於促性腺激素的配方 |
| CN105727260A (zh) * | 2016-02-03 | 2016-07-06 | 华侨大学 | 一种卵泡刺激素的长效制剂 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| CA3084689A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| SG11202005322RA (en) | 2017-12-07 | 2020-07-29 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals |
| FR3084584B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes |
| FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
| JP7425459B2 (ja) * | 2019-10-11 | 2024-01-31 | 株式会社シノテスト | 安定化されたｈｍｇｂ１含有溶液 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69524456T2 (de) | 1995-03-21 | 2002-08-01 | Applied Research Systems | Flüssige hcg-formulierungen |
| NZ332968A (en) * | 1996-05-29 | 2000-08-25 | Bioxid Oy | A controllably dissolvable silica-xerogel prepared via sol-gel |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| CA2335340C (en) * | 1998-07-23 | 2013-03-05 | Eli Lilly And Company | Fsh and fsh variant formulations, products and methods |
| ES2383994T3 (es) * | 2004-04-07 | 2012-06-28 | Ares Trading S.A. | Formulación líquida de hormona del crecimiento |
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| RS52106B (sr) * | 2008-02-08 | 2012-08-31 | Biogenerix Ag | Tečni preparat fsh |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| CN101614748A (zh) * | 2008-06-25 | 2009-12-30 | 上海新波生物技术有限公司 | 促卵泡激素时间分辨免疫荧光分析法及试剂盒 |
| SG176963A1 (en) * | 2009-06-22 | 2012-02-28 | Amgen Inc | Refolding proteins using a chemically controlled redox state |
| RU2553375C2 (ru) * | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
-
2010
- 2010-07-30 EP EP10171428A patent/EP2417982A1/en not_active Withdrawn
-
2011
- 2011-07-21 JO JOP/2011/0231A patent/JO3229B1/ar active
- 2011-07-25 TW TW100126190A patent/TWI439283B/zh active
- 2011-07-28 HU HUE11736111A patent/HUE033592T2/hu unknown
- 2011-07-28 LT LTEP11736111.3T patent/LT2598160T/lt unknown
- 2011-07-28 JP JP2013521146A patent/JP5860047B2/ja active Active
- 2011-07-28 US US13/704,771 patent/US8993732B2/en active Active
- 2011-07-28 CN CN201180037221.0A patent/CN103052398B/zh active Active
- 2011-07-28 AU AU2011284702A patent/AU2011284702C1/en active Active
- 2011-07-28 RS RS20170265A patent/RS55772B1/sr unknown
- 2011-07-28 PL PL11736111T patent/PL2598160T3/pl unknown
- 2011-07-28 HR HRP20170386TT patent/HRP20170386T1/hr unknown
- 2011-07-28 SI SI201131132A patent/SI2598160T1/sl unknown
- 2011-07-28 EP EP16195020.9A patent/EP3144010A1/en not_active Withdrawn
- 2011-07-28 WO PCT/EP2011/062986 patent/WO2012013742A2/en not_active Ceased
- 2011-07-28 KR KR1020187001203A patent/KR101991756B1/ko active Active
- 2011-07-28 CA CA2805864A patent/CA2805864A1/en active Pending
- 2011-07-28 CN CN201510508334.4A patent/CN105106939A/zh active Pending
- 2011-07-28 DK DK11736111.3T patent/DK2598160T3/en active
- 2011-07-28 BR BR112013002312-0A patent/BR112013002312B1/pt active IP Right Grant
- 2011-07-28 ES ES11736111.3T patent/ES2623634T3/es active Active
- 2011-07-28 MX MX2016010733A patent/MX356951B/es unknown
- 2011-07-28 PT PT117361113T patent/PT2598160T/pt unknown
- 2011-07-28 RU RU2012157154/15A patent/RU2574012C2/ru active
- 2011-07-28 KR KR1020137002504A patent/KR101820115B1/ko active Active
- 2011-07-28 NZ NZ606366A patent/NZ606366A/en unknown
- 2011-07-28 EP EP11736111.3A patent/EP2598160B1/en active Active
- 2011-07-28 NZ NZ628962A patent/NZ628962A/en unknown
- 2011-07-28 MX MX2013000681A patent/MX341464B/es active IP Right Grant
- 2011-07-29 AR ARP110102766A patent/AR082776A1/es not_active Application Discontinuation
- 2011-07-30 SA SA114350786A patent/SA114350786B1/ar unknown
-
2012
- 2012-12-13 ZA ZA2012/09497A patent/ZA201209497B/en unknown
- 2012-12-24 IL IL223821A patent/IL223821A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,382 patent/US9463221B2/en active Active
- 2015-12-17 JP JP2015245748A patent/JP2016102127A/ja active Pending
-
2016
- 2016-09-06 US US15/257,402 patent/US20170216405A1/en not_active Abandoned
-
2017
- 2017-01-03 IL IL249920A patent/IL249920A0/en unknown
- 2017-11-02 JP JP2017212395A patent/JP6522711B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341464B (es) | Estabilización de fsh. | |
| MY170302A (en) | Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use | |
| MX354021B (es) | Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona. | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| JO3241B1 (ar) | عملية لتحضير محلول مائي يتألف على الاقل من كربونات هيدروجين الكيل خبأ واستخدامه | |
| AU2012265219A8 (en) | Compounds containing hydrido-tricyano-borate anions | |
| PH12015502839A1 (en) | Antiviral compounds | |
| MY183312A (en) | Pharmaceutical formulation | |
| GEP20227397B (en) | Inhibitors of influenza viruses replication | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX367286B (es) | Composiciones de dexmedetomidina intranasal y sus metodos de uso. | |
| GB201113754D0 (en) | Composition | |
| TN2013000310A1 (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
| IN2014CN04530A (ar) | ||
| MX352563B (es) | Composiciones para el cuidado oral que contienen carbonato de calcio y silice. | |
| IN2014MN00859A (ar) | ||
| MX2013009259A (es) | Dispersiones oleosas de agroquimicos estables. | |
| MX340147B (es) | Composiciones farmacéuticas y nutracéuticas del ácido abscísico. | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| MX2012010127A (es) | Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos. | |
| MX337612B (es) | Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico. | |
| TR201009168A2 (tr) | Suda dağılan sefpodoksim proksetil formülasyonları. | |
| ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
| IN2013MU02442A (ar) | ||
| WO2013064326A3 (de) | Arjunolsäure zur erhöhung der sebumproduktion |